NCT06866509

To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients

A Prospective, Multicenter, Non-Interventional Observational Study to Investigate Changes in Blood Lipid Levels and Safety Following Administration of Litorvazet® Tablets in Patients With Dyslipidemia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,000 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study aims to investigate the lipid-lowering effects and safety of administering Litorvazet tablets (ezetimibe/atorvastatin) over a 24-week period in patients with dyslipidemia scheduled to receive Litorvazet tablets in a real-world clinical setting.

Detailed description

In a real-world clinical setting, Litorvazet® tablets will be administered to patients based on the investigator's medical judgment in accordance with the approved prescribing information (indications, dosage, and administration, precautions for use, etc.). Participants for data collection in this study will be patients diagnosed with dyslipidemia as determined by the judgment of their attending physician. All treatments, including drug administration and clinical laboratory tests conducted after the administration of Litorvazet® tablets, will be carried out based solely on the investigator's (attending physician's) medical judgment and will not be influenced by the patient's participation in the study. Information relevant to this observational study will be collected for up to 24 weeks.

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	Litorvazet Tablet 10/10mg	Ezetimibe 10 mg + Atorvastatin 10 mg
DRUG	Litorvazet Tablet10/20mg	Ezetimibe 10 mg + Atorvastatin 20 mg
DRUG	Litorvazet Tablet 10/40mg	Ezetimibe 10 mg + Atorvastatin 40 mg

Timeline

• Start date: 2022-02-28
• Primary completion: 2023-12-31
• Completion: 2024-02-28
• First posted: 2025-03-10
• Last updated: 2025-04-17

Locations

1 site across 1 country: South Korea